Baricent
Generic Name
Baricitinib
Manufacturer
Local Pharmaceutical Company
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| baricent 2 mg tablet | ৳ 25.00 | ৳ 250.00 |
Description
Overview of the medicine
Baricitinib is a Janus kinase (JAK) inhibitor used to treat moderate to severe active rheumatoid arthritis, moderate to severe atopic dermatitis, severe alopecia areata, and hospitalized adults with COVID-19 requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO.
Uses & Indications
Dosage
Adults
Rheumatoid Arthritis & Atopic Dermatitis: 2 mg once daily; may increase to 4 mg once daily based on clinical response. COVID-19: 4 mg once daily for 14 days or until hospital discharge. Alopecia Areata: 2 mg once daily, may increase to 4 mg once daily.
Elderly
No specific dose adjustment based on age alone. Monitor renal function and consider dose reduction if renal impairment is present.
Renal_impairment
Creatinine Clearance (CrCl) 30 to <60 mL/min: 1 mg once daily. CrCl <30 mL/min: Not recommended for RA, AD, AA. For COVID-19, 2 mg once daily.
How to Take
Take orally with or without food, at the same time each day. Swallow the tablet whole; do not split, crush, or chew.
Mechanism of Action
Baricitinib selectively and reversibly inhibits Janus kinase (JAK) enzymes, particularly JAK1 and JAK2. JAK enzymes are involved in signaling pathways of various cytokines and growth factors, essential for hematopoiesis and immune cell function. By inhibiting JAK1 and JAK2, Baricitinib interferes with the signaling of cytokines like IL-6, IL-23, and IFN-gamma, thereby reducing inflammation and immune response.
Pharmacokinetics
Onset
Clinical improvement observed within 1-2 weeks for rheumatoid arthritis, 2-4 weeks for atopic dermatitis. Full effect may take longer.
Excretion
Primarily renal excretion (approximately 75% unchanged drug), with some fecal excretion.
Half life
Approximately 12-16 hours.
Absorption
Rapidly absorbed with a peak plasma concentration (Tmax) of 1-2 hours. Absolute bioavailability is approximately 79%.
Metabolism
Primarily metabolized by CYP3A4 to a minor extent; most of the drug is excreted unchanged.
Side Effects
Contraindications
- •Hypersensitivity to baricitinib or any excipient of the formulation
- •Pregnancy
- •Severe active infections, including localized infections
- •Active tuberculosis
Drug Interactions
Probenecid
Increases baricitinib exposure (inhibits OAT3 transporter). Consider reducing baricitinib dose when co-administered (e.g., from 4 mg to 2 mg, or 2 mg to 1 mg daily).
Live vaccines
Avoid administering live vaccines during and immediately prior to baricitinib therapy.
Immunosuppressants (e.g., cyclosporine, azathioprine)
Increased risk of infection when co-administered. Concomitant use with other potent immunosuppressants (e.g., biologic DMARDs) is not recommended.
Storage
Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.
Overdose
No specific antidote. Management of overdose should consist of symptomatic and supportive treatment. Hemodialysis may remove some baricitinib from the systemic circulation.
Pregnancy & Lactation
Pregnancy: Contraindicated. May cause fetal harm. Women of childbearing potential should use effective contraception during treatment and for at least 1 week after the last dose. Lactation: Not recommended. Excreted in human milk. Discontinue breastfeeding during treatment and for at least 1 week after the last dose.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from manufacturing date
Availability
Pharmacies, Hospitals
Approval Status
FDA Approved
Patent Status
Patented (original molecule), generic versions available
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
